Posterior subtenon triamcinolone injection in cystoid macular edema secondary to uveitis.

Dr Sharad Gupta; Dr Vinit Kumar Kamble

Volume : VIII, Issue : II, February - 2019

Posterior subtenon triamcinolone injection in cystoid macular edema secondary to uveitis.

Dr Sharad Gupta, Dr Vinit Kumar Kamble

Abstract :

Aim: To evaluate the efficacy of posterior sub–tenon triamcinolone injection in cystoid macular edema secondary to uveitis: : A Hospital–based Prospective Interventional study. Methods: All patients fulfilling the diagnostic criteria were included from 1 January 2012 to 30 June 2013: received PST (20mg/ 0.5ml) and asked to follow up at 3, 8, and 12 weeks respectively, to assess the positive effects including improvement in visual acuity LogMAR and reduction in mean central macular thickness. Results: Out of 27 eyes of 23 patients, the mean age was 33.91 ± 14.65 (19–62 years). Nine (39.14%) patients were male. Nineteen patients (50.7 %) had unilateral involvement. Out of 23 patients, 21 (91.30%) had intermediate uveitis and 2 (8.70%) had posterior uveitis. The mean LogMAR BCVA was improved from 0.83± 0.19 at baseline to 0.30 ± 0.20 at 12 weeks. (p < 0.05). Improvement in visual acuity by greater than two lines was observed in 21 (77.77%) eyes and that by 2–line improvement in 5 (18.53%) eyes and no improvement was noted in 1 (3.70%) eye at the end of the study. The mean CMT before injection was 461.10 ± 120µm at baseline with mean reduction of 295.93 ± 81 µm (35%) at 12 weeks (p < 0.05). No statistically significant rise in IOP was observed during the study period. Conclusion: No side effects was observed during the study period, and found to be a safe and effective form of treatment in uveitic macular edema.